Thalidomide-related adverse events
During 6 months follow-up, adverse events were reported in 48 (63.2%) patients, including dizziness and/or lethargy (n=24), constipation(n=9), abdominal pain and/or vomiting and/or nausea (n=9), arthralgia (n=4), edema (n=3), peripheral neuropathy (numbness of extremities) and/or headache(n=2), skin rash (n=1),leukocytopenia (n=7), neutrophil (n=10), thrombocytosis (n=9). Two patients stopped using thalidomide due to adverse events, including central venous thrombosis (n=1) and seizure (n=1). Most the symptoms relieved spontaneously without withdraw, while some symptoms relieved with temporary reduced dosage.